The purpose of this study is to assess the safety and effectiveness of buprenorphine for treatment of concurrent intravenous heroin and cocaine dependence...
Date First Received: September 20, 1999
Last Updated: June 23, 2005
Verified by: National Institute on Drug Abuse (NIDA), December 2002
Clinical Trial Phase: Phase 2 | Start Date:
Overall Status: Completed
Estimated Enrollment: 0
Brief Summary
Official Title: “Treatment Efficacy for Drug Abuse and AIDS Prevention”
Condition Keyword(s):
Intervention(s):
The purpose of this study is to assess the safety and effectiveness of buprenorphine for treatment of concurrent intravenous heroin and cocaine dependence.
Study Type: Interventional
Study Design: Treatment
Intervention(s) in this Clinical Trial
- Drug: Buprenorphine
Criteria for Participation in this Clinical Trial
- Please contact site for information.
Gender Eligibility for this Clinical Trial: Male
Minimum Age for this Clinical Trial: 26 Years
Maximum Age for this Clinical Trial: 41 Years
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Sponsor Information
Lead Sponsor: National Institute on Drug Abuse (NIDA)
Overall Clinical Trial Officials and Contacts
Jack Mendelson, M.D. Principal Investigator Mclean Hospital
Additional Information
Information obtained from ClinicalTrials.gov on October 10, 2008
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00000211
Study ID Number: NIDA-06116-2
ClinicalTrials.gov Identifier: NCT00000211
Health Authority: United States: Federal Government
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
